OSE IMMUNO (OSE.PA) Stock Price & Overview

EPA:OSE • FR0012127173

Current stock price

3.038 EUR
+0.02 (+0.73%)
Last:

The current stock price of OSE.PA is 3.038 EUR. Today OSE.PA is up by 0.73%. In the past month the price decreased by -29.51%. In the past year, price decreased by -48.51%.

OSE.PA Key Statistics

52-Week Range2.872 - 7.7
Current OSE.PA stock price positioned within its 52-week range.
1-Month Range2.872 - 4.38
Current OSE.PA stock price positioned within its 1-month range.
Market Cap
68.233M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.59
Dividend Yield
N/A

OSE.PA Stock Performance

Today
+0.73%
1 Week
-11.69%
1 Month
-29.51%
3 Months
-38.33%
Longer-term
6 Months -48.33%
1 Year -48.51%
2 Years -37.49%
3 Years -40.31%
5 Years -75.70%
10 Years -59.49%

OSE.PA Stock Chart

OSE IMMUNO / OSE Daily stock chart

OSE.PA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to OSE.PA. When comparing the yearly performance of all stocks, OSE.PA is a bad performer in the overall market: 97.03% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

OSE.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to OSE.PA. While OSE.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OSE.PA Earnings

Next Earnings DateN/A
Last Earnings DateMar 24, 2026
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

OSE.PA Forecast & Estimates

7 analysts have analysed OSE.PA and the average price target is 15.16 EUR. This implies a price increase of 399.14% is expected in the next year compared to the current price of 3.038.

For the next year, analysts expect an EPS growth of -117.49% and a revenue growth -46.75% for OSE.PA


Analysts
Analysts80
Price Target15.16 (399.01%)
EPS Next Y-117.49%
Revenue Next Year-46.75%

OSE.PA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

OSE.PA Financial Highlights

Over the last trailing twelve months OSE.PA reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS decreased by -191.65% compared to the year before.


Income Statements
Revenue(TTM)2.22M
Net Income(TTM)-34.84M
Industry RankSector Rank
PM (TTM) N/A
ROA -33.44%
ROE -68.84%
Debt/Equity 0.64
Chartmill High Growth Momentum
EPS Q2Q%-130.08%
Sales Q2Q%-98.36%
EPS 1Y (TTM)-191.65%
Revenue 1Y (TTM)-97.34%

OSE.PA Ownership

Ownership
Inst Owners3.59%
Shares22.46M
Float16.27M
Ins Owners25.4%
Short Float %N/A
Short RatioN/A

About OSE.PA

Company Profile

OSE logo image OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 68 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

Company Info

IPO: 2015-03-30

OSE IMMUNO

22, boulevard Benoni Goullin

Nantes PAYS DE LA LOIRE FR

Employees: 52

OSE Company Website

OSE Investor Relations

Phone: 33228291010

OSE IMMUNO / OSE.PA FAQ

What does OSE do?

OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 68 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.


What is the stock price of OSE IMMUNO today?

The current stock price of OSE.PA is 3.038 EUR. The price increased by 0.73% in the last trading session.


Does OSE stock pay dividends?

OSE.PA does not pay a dividend.


What is the ChartMill rating of OSE IMMUNO stock?

OSE.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the valuation of OSE IMMUNO (OSE.PA) based on its PE ratio?

OSE IMMUNO (OSE.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.59).


Can you provide the market cap for OSE IMMUNO?

OSE IMMUNO (OSE.PA) has a market capitalization of 68.23M EUR. This makes OSE.PA a Micro Cap stock.